Document:

Exhibit 10.2

     

    Execution Version

    

    

    SPONSOR SUPPORT AGREEMENT

     

    This SPONSOR SUPPORT AGREEMENT (this “Agreement”), dated as of October 19, 2022, is made by and among Rose Hill Acquisition Corporation, an exempted company incorporated with limited liability
      in the Cayman Islands (“SPAC”), Inversiones e Inmobilaria GHC Ltda, a limited liability company organized under the laws of Chile (the “Company”) and Rose Hill Sponsor LLC, a Delaware limited liability company (“Sponsor”), and
      the undersigned individual (collectively, together with Sponsor, the “Sponsor Parties”). SPAC, the Company and the Sponsor Parties shall be referred to herein from time to time collectively as the “Parties.” Capitalized terms used but
      not otherwise defined herein shall have the meanings ascribed to such terms in the Business Combination Agreement (as defined below).

    

    

    WHEREAS, SPAC, the Company and Alejandro García Huidobro Empresario Individual have entered into that certain Business Combination Agreement, dated as of the date hereof (as it may be amended,
      restated or otherwise modified from time to time in accordance with its terms, the “Business Combination Agreement”); and

    

    

    WHEREAS, as of the date hereof, the Sponsor Parties are the record and beneficial owners of all of the issued and outstanding SPAC Shares and SPAC Warrants set forth under such Person’s name on the
      signature pages hereto.

    

    

    NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
      the Parties, each intending to be legally bound, hereby agree as follows:

     

    1.        Non Redemption. Each Sponsor Party hereby irrevocably and unconditionally agrees that if SPAC seeks shareholder approval of (a) the
      transactions contemplated by the Business Combination Agreement or any Transaction Agreement or (b) the Extension Proposal, it or he shall not redeem any SPAC Shares owned by it or him in connection with any such shareholder approval. This Section
        1 shall be void and of no force and effect if the Business Combination Agreement shall be terminated in accordance with its terms.

     

    2.           Voting.

     

    (a)        Until the earlier of (a) the Closing or (b) termination of the Business Combination Agreement in accordance with its terms, at each general
      meeting of the SPAC Shareholders (whether annual or extraordinary and whether or not an adjourned or postponed meeting, however called), and in each written consent or resolution of any of the SPAC Shareholders in which such Sponsor Party is entitled
      to vote or consent, such Sponsor Party hereby unconditionally and irrevocably agrees to be present for such meeting (or otherwise cause its or his Subject Securities to be counted as present thereat for the purpose of establishing a quorum) and vote
      (in person or by proxy), or consent to any action by written consent or resolution with respect to, as applicable, the Subject Securities (a) in favor of, and to approve and adopt, the Business Combination Agreement, the Transaction Agreements, the
      Transactions and all SPAC Shareholder Matters, (b) in favor of and to approve and adopt, all other matters contemplated to be adopted or approved by the SPAC Shareholders as set forth in the Business Combination Agreement or any of the Transaction
      Agreements or in connection with the Transactions, including the Extension Proposal, and (c) in opposition to: (i) any SPAC Business Combination and any and all other proposals (A) that could reasonably be expected to delay or impair the ability of
      SPAC to consummate any of the Transactions or (B) which are in competition with or materially inconsistent with the Business Combination Agreement, any Transaction Agreement or any of the Transactions or (ii) any other action, proposal, transaction
      or agreement involving SPAC that is intended, or would reasonably be expected, to prevent, impede, interfere with, delay, postpone or adversely affect in any material respect any of the Transactions or would reasonably be expected to result in (A)
      any breach of any representation, warranty, covenant, obligation or agreement of the SPAC in the Business Combination Agreement or any Transaction Agreement or (B) any of the conditions to SPAC’s or the Company Parties’ obligations under the Business
      Combination Agreement or any Transaction Agreement not being fulfilled. For purposes of this Agreement “Subject Securities” shall mean, with respect to a Sponsor Party, such Sponsor Party’s SPAC Shares and any other equity securities of SPAC
      that such Sponsor Party holds of record or beneficially as of the date of this Agreement or acquires record or beneficial ownership of after the date hereof, including any SPAC Warrants or other securities convertible into or exercisable or
      exchangeable for SPAC Shares.

     

    
      1

      
        

    

    (b)        Prior to the Closing, each Sponsor Party agrees not to deposit, and to cause its Affiliates not to deposit, any Subject Securities in a voting
      trust or subject any Subject Securities to any arrangement or agreement with respect to the voting of such Subject Securities, unless specifically requested to do so by New PubCo, the Company and SPAC in connection with the Business Combination
      Agreement, any Transaction Agreement or the Transactions.

     

    (c)          The obligations of each Sponsor Party specified in this Section 2 shall (i) apply whether or not any of the Transactions is recommended
      by the board of directors of SPAC, and whether or not any previous such recommendation has been withdrawn, modified, qualified or otherwise changed by the board of directors of SPAC and (ii) be void and of no force and effect if the Business
      Combination Agreement shall be terminated in accordance with its terms.

     

    3.        Information. Prior to the Closing, each Sponsor Party agrees to provide to SPAC, the Company, and their respective Representatives, any
      information regarding such Sponsor Party or its Subject Securities that is reasonably requested by SPAC, the Company any of their respective Representatives pursuant to the Business Combination Agreement or any Transaction Agreement.  To the extent
      required by applicable Legal Requirements, each Sponsor Party authorizes the Company and SPAC to publish and disclose in any announcement or disclosure required by the SEC, NASDAQ or the Registration Statement (including all documents and schedules
      filed with the SEC in connection with any of the foregoing), such Sponsor Party’s identity and ownership of its Subject Securities and the nature of such Sponsor Party’s commitments and agreements under this Agreement, the Business Combination
      Agreement and any other Transaction Agreement; provided that such disclosure is made in compliance with the provisions of this Agreement and the Business Combination Agreement. This Section 3 shall be void and of no force and effect if the
      Business Combination Agreement shall be terminated in accordance with its terms.

     

    4.           Transfer Restrictions.

     

    (a)          Except as expressly contemplated by the Business Combination Agreement or this Agreement or with the prior written consent of SPAC and the
      Company prior to the Closing and between the date hereof and the Closing Date, each Sponsor Party agrees that it or he shall not Transfer (as defined below) any Subject Securities.  “Transfer” shall mean the (i) sale of, offer to sell,
      contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation with respect to
      or decrease of a call equivalent position within the meaning of Section 16 of the Exchange Act, (ii) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any
      security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (iii) public announcement of any intention to effect any transaction specified in clause (i) or (ii).

     

    
      2

      
        

    

    (b)        Notwithstanding the provisions set forth in Section 4(a), Transfers of the Subject Securities are permitted: (i) in the case of an
      individual, (A) by gift to a member of the individual’s immediate family, or to a trust, the beneficiary of which is a member of the individual’s immediate family or an Affiliate of such Person, or to a charitable organization, (B) by virtue of laws
      of descent and distribution upon death of the individual, (C) pursuant to a qualified domestic relations order, (D) in the case of a trust, by distribution to one or more of the permissible beneficiaries of such trust or (ii) in the case of an
      entity, to an Affiliate of such Person; provided, that, in the case of clauses (i) and (ii), these permitted transferees must enter into a written agreement with SPAC, the Company and New PubCo following its incorporation agreeing to be bound by the
      applicable provisions of this Agreement.

     

    (c)         This Section 4 shall be void and of no force and effect if the Business Combination Agreement shall be terminated in accordance with its
      terms.

     

    5.        Waiver of Anti-Dilution Rights.  Contingent upon and effective as of the Closing, pursuant to Article 24(b) of the Amended and Restated
      Memorandum and Articles of Association of SPAC (the “SPAC Articles”), each Sponsor Party in its capacity as holder of SPAC Class B Ordinary Shares hereby irrevocably and unconditionally waives and covenants and agrees not to exercise, assert
      or perfect, any rights to adjustment or other anti-dilution protections with respect to the Initial Conversion Ratio (as defined in the SPAC Articles). This Section 5 shall be void and of no force and effect if the Business Combination
      Agreement shall be terminated in accordance with its terms.

     

    6.           Vesting Shares.

     

    (a)        Effective as of, and contingent upon the Second Effective Time, upon receipt thereof, 700,000 New PubCo Ordinary Shares (the “Vesting Shares”)
      received by the Sponsor shall be deemed unvested; provided, however:

     

    (i)          400,000 Vesting Shares shall be deemed to have vested and shall cease to be subject to the restrictions and forfeiture provisions under this Section
        6 if at any time following the Closing and prior to the five (5) year anniversary of the Closing (the “Specified Period”) the VWAP of the New PubCo Ordinary Shares is greater than or equal to $15.00 over any twenty (20) Trading Days
      within any consecutive thirty (30) Trading Day period; provided, that if such shares have not vested prior to the expiration of the Specified Period then such shares shall be irrevocably forfeited and
      surrendered to New PubCo for no consideration on the first (1st) Business Day following the expiration of the Specified Period; and

     

    (ii)         300,000 Vesting Shares shall be deemed to have vested and shall cease to be subject to the restrictions and forfeiture provisions under this Section
        6 if at any time during the Specified Period the VWAP of the New PubCo Ordinary Shares is greater than or equal to $20.00 over any twenty (20) Trading Days within any consecutive thirty (30) Trading Day period; provided, that if such shares have not vested prior to the expiration of the Specified Period then such shares shall be irrevocably forfeited and surrendered to New PubCo for no consideration on the first (1st) Business Day following the expiration of the Specified Period.

     

    (b)          Notwithstanding anything to the contrary, in the event of a transaction that results in:

     

    (i)         a Change of Control, then any unvested Vesting Shares that have not otherwise been previously forfeited pursuant to Section 6(a) shall
      be deemed to have vested and shall cease to be subject to the restrictions and applicable forfeiture provisions under this Section 6 effective as of immediately prior to the consummation of such transaction; or

     

    
      3

      
        

    

    (ii)         New PubCo Ordinary Shares being converted into the right to receive cash or other consideration having a value (in the case of any non-cash
      consideration, as provided in the definitive transactions documents for such transaction, or if not so provided, determined by the New PubCo Board in good faith) equal to or in excess of the VWAP of the New PubCo Ordinary Shares specified in Section
        6(a) (an “Earn-Out Target”) that does not constitute a Change of Control, then the Vesting Shares subject to the applicable Earn-Out Target that have not been previously been deemed vested pursuant to Section 6(a) shall be deemed
      to have vested and shall cease to be subject to the restrictions and forfeiture provisions under this Section 6 immediately prior to the consummation of such transaction.

     

    (c)       Following the Closing, the Sponsor shall not Transfer any of its Vesting Shares so long as such shares remain unvested; provided, however, that
      Transfers of the Vesting Shares are permitted: (i) in the case of an individual, (A) by gift to a member of the individual’s immediate family, or to a trust, the beneficiary of which is a member of the individual’s immediate family or an Affiliate of
      such Person, or to a charitable organization, (B) by virtue of laws of descent and distribution upon death of the individual, (C) pursuant to a qualified domestic relations order, (D) in the case of a trust, by distribution to one or more of the
      permissible beneficiaries of such trust or (ii) in the case of an entity, to an Affiliate of such Person; provided, that, in the case of clauses (i) and (ii), these permitted transferees must enter into a written agreement with the Company and New
      PubCo following its incorporation agreeing to be bound by the applicable provisions of this Agreement.

     

    (d)        The registered holder(s) of any Vesting Shares that remain unvested as of any time shall be entitled to all of the rights of ownership thereof,
      including the right to vote and receive dividends and other distributions in respect of such Vesting Shares.  Notwithstanding the foregoing, to the extent that any dividends or other distributions are paid in cash in respect of any Vesting Shares
      that have not vested in accordance with Section 6(a), such dividends and distributions shall be set aside by and paid to the holder(s) thereof as promptly as reasonably practicable following the vesting of such Vesting Shares (if at all).

     

    (e)        New PubCo’s register of members and all certificates or book entries representing unvested Vesting Shares shall bear a legend referencing that
      they are subject to forfeiture and restrictions on transfer, as applicable, pursuant to the provisions of this Agreement, and any transfer agent for New PubCo will be given appropriate stop transfer orders with respect to such unvested Vesting
      Shares. Upon vesting of the applicable Vesting Shares, New PubCo shall promptly take all actions necessary to cause such legends to be removed.

     

    (f)        The Earn-Out Targets and the Vesting Shares, until such time as such Vesting Shares have been forfeited or have otherwise vested pursuant to this
      Section 6, shall be equitably adjusted for (other than with respect to the Transactions) any share split, division or subdivision of shares, share dividend or distribution (including any dividend or distribution of securities convertible into
      New PubCo Ordinary Shares), reorganization, combination, exchange of shares, reverse share split, consolidation of shares, reclassification, recapitalization or other like change affecting (i) SPAC Class B Ordinary Shares until immediately prior to
      the First Effective Time and (ii) the New PubCo Ordinary Shares after the First Effective Time.

     

    (g)         This Section 6 shall be void and of no force and effect if the Business Combination Agreement shall be terminated in accordance with its
      terms.

     

    7.          Warrants. Sponsor hereby agrees that, subject to and contingent upon the First Effective Time,
        automatically and without any further action by any other Person, Sponsor shall forfeit a number of Parent Warrants such that immediately following such forfeiture Sponsor owns 3,050,000 Private Placement Warrants immediately prior to the First
        Effective Time (such forfeited Private Placement Warrants, the “Forfeited Private Placement Warrants”), and all such Forfeited Private Placement Warrants shall be cancelled and forfeited for no consideration and shall cease to exist. 
      This Section 7 shall be void and of no force and effect if the Business Combination Agreement shall be terminated in accordance with its terms.

     

    
      4

      
        

    

    8.           Other Covenants; Acknowledgement.

     

    (a)       Each Sponsor Party agrees not to, directly or indirectly, take any action, or authorize or knowingly permit any of its Affiliates or
      representatives to take any action on its behalf, that would be a breach of Section 7.4(b) (Confidentiality; Communications Plan; Access to Information) or Section 7.10 (No Solicitation) of the Business Combination Agreement if such action were taken
      by SPAC.

     

    (b)         Each Sponsor Party hereby agrees not to commence or participate in any claim, derivative or otherwise, against the Company, SPAC or any of their
      respective Affiliates (i) challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement or (ii) alleging a breach of any fiduciary duty of the board of directors of SPAC in connection with the Business
      Combination Agreement, the Transaction Agreements, the Transactions, the Extension Proposal and all SPAC Shareholder Matters.

     

    (c)        The Sponsor acknowledges and agrees that it shall be deemed the “SPAC Sponsor” for all purposes under Section 3.11 (Transaction Expense Payment;
      Excess Transaction Expense Amount) of the Business Combination Agreement and to be bound by, and subject to, the provisions set forth in Section 3.11 (Transaction Expense Payment; Excess Transaction Expense Amount) of the Business Combination
      Agreement applicable to the SPAC Sponsor.

     

    (d)        Each Sponsor Party acknowledges and agrees that the Company and SPAC are entering into the Business Combination Agreement in reliance upon such
      Sponsor Party entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the agreements, covenants and obligations contained in this Agreement and but for such Sponsor Party entering into this
      Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the agreements, covenants and obligations contained in this Agreement the Company and SPAC would not have entered into, or agreed to consummate the
      transactions contemplated by, the Business Combination Agreement.

     

    (e)         This Section 8 shall be void and of no force and effect if the Business Combination Agreement shall be terminated in accordance with its
      terms.

     

    9.          Entire Agreement; Amendments and Waivers.  This Agreement and the other agreements referenced herein constitute the entire agreement and
      understanding of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject
      matter hereof or the transactions contemplated hereby.  This Agreement may not be changed, amended, modified or waived as to any particular provision, except by a written instrument executed (i) prior to Closing, among the SPAC, Sponsor, New PubCo
      (assuming its incorporation at such time) and the Company or (ii) after the Closing, between Sponsor and New PubCo.

     

    10.         Successors and Assigns.  No party hereto may, except as set forth herein, assign either this Agreement or any of its rights, interests,
      or obligations hereunder without the prior written consent of the other parties.  Any purported assignment in violation of this Section shall be void and ineffectual and shall not operate to transfer or assign any right, interest or obligation to the
      purported assignee.  This Agreement shall be binding on, and inure to the benefit of, each of the parties hereto and their respective successors and permitted assigns.

     

    
      5

      
        

    

    11.         Notices.  Any notice, consent or request to be given in connection with any of the terms or provisions of this Agreement shall be in
      writing and shall be sent or given (i) if sent or given to any party hereto other than a Sponsor Party, to such party in accordance with the terms of Section 11.1 (Notices) of the Business Combination Agreement or (ii) if given to a Sponsor Party, to
      such Sponsor Party at the address or e-mail set forth on such Sponsor Party’s signature page hereto and shall, in each case, be deemed delivered in accordance with the terms of Section 11.1 (Notices) of the Business Combination Agreement.

     

    12.        Termination.  This Agreement shall terminate at such time, if any, as the Business Combination Agreement is terminated in accordance with
      its terms prior to the Closing.  In the event that the Business Combination Agreement is terminated in accordance with its terms prior to the Closing, this Agreement shall be of no force and effect from and after such termination.  No termination of
      this Agreement shall relieve any party hereto from any obligation accruing, or liability resulting from a Willful Breach of this Agreement by such party occurring prior to such termination or reversion.

     

    13.         Representations and Warranties.

     

    (a)        Each of the Parties represents and warrants that (a) it has the power and authority, or capacity, as the case may be, to enter into this Agreement
      and to carry out its obligations hereunder, (b) the execution and delivery of this Agreement and the performance of its obligations hereunder have been duly and validly authorized by all corporate or limited liability company action on its part and
      (c) this Agreement has been duly and validly executed and delivered by each of the parties hereto and constitutes, a legal, valid and binding obligation of each such party enforceable in accordance with its terms, except as such enforceability may be
      limited by bankruptcy Legal Requirements, other similar Legal Requirements affecting creditors’ rights and general principles of equity affecting the availability of specific performance and other equitable remedies.

     

    (b)        Each Sponsor Party represents and warrants that it is the record and “beneficial owner” (within the meaning of
        Rule 13d-3 under the Exchange Act) of, and has good title to, all of such Sponsor Party’s SPAC Shares and SPAC Warrants, and there exist no Liens or any other limitation or restriction (including any restriction on the right to vote, sell or
        otherwise dispose of such SPAC Shares and SPAC Warrants (other than transfer restrictions under the Securities Act)) affecting any such SPAC Shares or SPAC Warrants, other than Liens pursuant to (i) this Agreement, (ii) applicable Governing
        Documents, (iii) the Business Combination Agreement, (iv) the agreements entered into by Sponsor with SPAC in connection with SPAC’s initial public offering or (v) any applicable securities Legal Requirements. Such Sponsor Party’s SPAC Shares and
        SPAC Warrants are the only equity securities in SPAC owned of record or beneficially by such Sponsor Party on the date of this Agreement, and none of such Sponsor Party’s SPAC Shares or SPAC Warrants are subject to any proxy, voting trust or other
        agreement or arrangement with respect to the voting of such SPAC Shares or SPAC Warrants, except as provided hereunder and pursuant to the Current Sponsor Letter Agreement. Other than its SPAC Warrants and the SPAC Shares, each Sponsor Party does
        not hold or own any rights to acquire (directly or indirectly) any equity securities of SPAC or any equity securities convertible into, or which can be exchanged for, equity securities of SPAC.

     

    14.        Further Assurances.  Each of the Parties agrees to execute and deliver hereafter any further document, agreement or instrument of
      assignment, Transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof and as may be reasonably requested in writing by another party hereto.

     

    15.       Miscellaneous.  Sections 11.2 (Interpretation), 11.3 (Counterparts; Electronic Delivery), 11.5 (Severability), 11.6 (Other Remedies;
      Specific Performance), 11.7 (Governing Law), 11.8 (Consent to Jurisdiction; Waiver of Jury Trial), 11.9 (Rules of Construction) and 11.14 (No Recourse) of the Business Combination Agreement shall apply mutatis mutandis to this Agreement.

     

    [signature page follows]

     

    

    
      6

      
        

    

    IN WITNESS WHEREOF, each of the Parties has caused this
        Agreement to be duly executed on its behalf as of the day and year first above written.

     

    	 	
            ROSE HILL SPONSOR LLC

          
	 	 	 	 
	 	
            By:

          	
            /s/ Albert Hill IV

          
	 	 	
            Name:

          	
            Albert Hill IV

          
	 	 	
            Title:

          	
            Managing Member

          

    

    

    	 	
            Attn:

          	
            Albert Hill IV

          
	 	 	 
	 	
            Email:

          	
            [****]

          
	 	 	 
	 	
            Address:

          	
            Rose Hill Sponsor LLC

          
	 	 	
            981 Davis Drive

          
	 	 	
            Atlanta, GA 30327

          

    

    

    [Signature Page to Sponsor Support Agreement]

    

    

    
      
        

    

    IN WITNESS WHEREOF, each of the Parties has caused this
        Agreement to be duly executed on its behalf as of the day and year first above written.

     

    	 	
            ROSE HILL ACQUISITION CORPORATION

          
	 	 	 	 
	 	
            By:

          	
            /s/ Albert Hill IV

          
	 	 	
            Name:

          	
            Albert Hill IV

          
	 	 	
            Title:

          	
            Co-Chief Financial Officer

          

    

    

    [Signature Page to Sponsor Support Agreement]

    

    

    
      
        

    

    IN WITNESS WHEREOF, each of the Parties has caused this
        Agreement to be duly executed on its behalf as of the day and year first above written.

     

    	 	
            SPONSOR PARTY

          
	 	 	 	 
	 	
            By:

          	
            /s/ Albert Hill IV

          
	 	 	
            Name:

          	
            Albert Hill IV

          

    

    

    [Signature Page to Sponsor Support Agreement]

    

    

    
      
        

    

    IN WITNESS WHEREOF, each of the Parties has caused this
        Agreement to be duly executed on its behalf as of the day and year first above written.

     

    	 	
            INVERSIONES E INMOBILARIA GHC LTDA

          
	 	 	 	 
	 	
            By:

          	
            /s/ Alejandro Garcia Huidobro Empresario

          
	 	 	
            Name:

          	
            Alejandro Garcia Huidobro Empresario

          
	 	 	
            Title:

          	
            Administrator and Legal Representative

          

    

    

    [Signature Page to Sponsor Support Agreement]Exhibit
10.1
 

Certain
identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats
as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”

 

MASTER
SERVICES AGREEMENT

 

This
Master Services Agreement (this “Agreement”) is made as of October 24, 2022 (the “Effective Date”)
by and between Societal CDMO, Inc., a Pennsylvania corporation, with its principal place of business at 1300 Gould Dr., Gainesville,
GA 30504 (collectively with each of its subsidiaries and affiliates, including IriSys, LLC and Recro Gainesville LLC, “Societal
CDMO”) and Cingulate Therapeutics LLC, a Delaware limited liability company with its principal place of business at 1901 W.
47th Place, 3rd Floor, Kansas City, Kansas 66205 (the “Client”). Societal CDMO and Client may
be individually referred to herein as a “Party” or may be collectively referred to herein as the “Parties”.

 

RECITALS

 

WHEREAS,
Societal CDMO is in the business of providing certain pharmaceutical development and/or technology transfer services, as may be described
from time to time in one or more Statements of Work.

 

WHEREAS,
Client desires to obtain from Societal CDMO certain services from time to time under the terms and conditions set forth herein, such
services up to but not including commercial production.

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants set forth below, the Parties, intending to be legally bound, hereby
agree as follows.

 

1.
DEFINITIONS: The following terms shall have the meanings set forth below:

 

1.1.
“Acceptance Criteria” means the tests and other factors set forth in the Master Batch Record and analytical and quality
documents.

 
   

1.2.
“Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended to date and as may be further amended
from time to time during the Term, and the regulations promulgated with respect thereto.

 
   

1.3.
“Affiliate” means any person, firm, trust, partnership, corporation, company or other entity or combination thereof
which, directly or indirectly, (i) controls a Party, (ii) is controlled by a Party, or (iii) is under common control with a Party. For
the purposes of this definition, the terms “control” and “controlled” means ownership of fifty
percent (50%) or more, including ownership by trusts with substantially the same beneficial interests, of the voting and equity rights
of such person, firm, trust, partnership, corporation, company or other entity or combination thereof or the power to direct the management
of such person, firm, trust, partnership, corporation, company or other entity or combination thereof.

 
   

1.4.
“Agreement” shall have the meaning set forth in the preamble.

 

1.5.
“API” means the active pharmaceutical ingredient of a drug product.

 

1.6.
“Bailed Property” has the meaning set forth in Section 5.1(a).

 

    	 

    	 

    

 

1.7.
“Batch” means a specific quantity of a drug or other material that is intended to have uniform character and quality
within specified limits and is produced according to a single manufacturing order during the same cycle of manufacture.

 

1.8.
“Batch Record” means the production record pertaining to a Batch.

 

1.9.
“Business Day” means any day except Saturday, Sunday or any other day on which commercial banks located in Atlanta,
Georgia are authorized or required by law to be closed for business.

 

1.10.
“Certificate of Analysis” means the document for API, Materials, work-in-process product or Product prepared by Societal
CDMO, reporting the results of testing conducted by Societal CDMO.

 

1.11.
“cGMP” means, as applicable, then-current good manufacturing practices as described in: (i) Parts 210 and 211 of Title
21 of the United States Code of Federal Regulations; (ii) Commission Directive (EU) 2017/1572 (art. 2); and (iii) Division 2 of Part
C of the Food and Drug Regulations (Canada); together with current final industry-accepted Health Canada, FDA, and European Medicines
Agency guidance documents pertaining to manufacturing and quality control practice, all as updated, amended, and revised from time to
time.

 

1.12.
“Change Order” means a written document executed by authorized representatives of both Parties which alters or modifies
a Statement of Work.

 

1.13.
“Client” shall have the meaning set forth in the preamble.

 

1.14.
“Client Capital Requirements” shall have the meaning set forth in Section 6.6.

 

1.15.
“Client Indemnitees” shall have the meaning set forth in Section 9.1.

 

1.16.
“Client’s Intellectual Property” means all Intellectual Property rights, worldwide, specific to any Product
or any generic version thereof or the development, manufacture, testing, storage packaging, use and/or sale of any Product, including,
but not limited to, any analytical methods, certified reference standards, impurity markers, manufacturing, storage, packaging processes
and procedures, specifications, batch records and control documents, raw materials and other materials, data or other information specific
to any Product (in each case, whether provided by or on behalf of Client to Societal CDMO in connection with this Agreement, or developed
by or on behalf of Societal CDMO, any of its Subcontractors or Affiliates or any of its or their respective personnel in connection with
this Agreement), and further including any Client Inventions.

 

1.17.
“Client Inventions” shall have the meaning set forth in Section 8.3.

 

1.18.
“Deficiencies” shall have the meaning set forth in Section 12.3.

 

1.19.
“Duties” shall have the meaning set forth in Section 4.3.

 

1.20.
“Effective Date” shall have the meaning set forth in the preamble.

 

    	-2-

     

    

 

1.21.
“Encumbrance” means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory
or other), option, security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind,
including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.

 

1.22.
“Finished Product” means Products that are Manufactured in accordance with the applicable Product Specifications,
cGMPs and other, Regulatory Standards, and the terms and conditions of this Agreement, the Quality Agreement and the applicable Statement
of Work, and released to Client in accordance with Section 2.10.

 

1.23.
“FDA” means the United States Food and Drug Administration or any successor agency thereto.

 

1.24.
“Governmental Authority” means any federal, state or other governmental department, governmental authority, or judicial
or administrative body, including, but not limited to, the FDA.

 

1.25.
“Initial Term” shall have the meaning set forth in Section 7.1.

 

1.26.
“Inspection Period” shall have the meaning set forth in Section 2.12.

 

1.27.
“Intellectual Property” shall include, without limitation, rights in patents, patent applications, formulae, trademarks,
trademark applications, trade names, trade dress, Trade Secrets, Inventions, discoveries, improvements, modifications, work product,
works-in-progress, data, records, reports, analytical methods, other methods and procedures, copyright, industrial designs, data and
know-how and all other intellectual and industrial property rights of any sort throughout the world now known or hereafter recognized.

 

1.28.
“Inventions” means any idea, concept, innovation, invention, improvement, development, discovery, technology, computer
program, device, work of authorship, reports, records, certificates, statements, data, formula, compound method, know-how, process, method,
technique, protocol or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it
is contained and whether or not patentable or copyrightable.

 

1.29.
“Losses” shall include all Third Party actions, causes of action, costs (including reasonable legal fees), claims,
damages, liabilities and expenses.

 

1.30.
“Manufacture” or “Manufacturing” means the manufacture, filling, finishing, sampling, testing,
labeling, packaging, release, storage, shipping and quality control of the Finished Products in accordance with the applicable Product
Specifications, cGMPs, Regulatory Standards, and the terms and conditions of this Agreement, the Quality Agreement and the applicable
Statement of Work.

 

1.31.
“Manufacturing Facility” means Societal CDMO’s premises and equipment located at any facility where manufacturing,
packaging, testing or storing of Product takes place.

 

1.32.
“Master Batch Record” means a master production and control record containing a written description of the procedure
to be followed for processing a Batch of Product including, but not limited to, a complete list of all active and inactive ingredients,
components, weights and measures, equipment setup and run parameters, descriptions of drug product containers, closures, packaging materials,
and labeling and complete specifications for each, within the meaning of 21 CFR part 211.186, or its successor as in effect from time
to time.

 

    	-3-

     

    

 

1.33.
“Materials” shall include all materials and supplies required to perform the Services, including API, certain analytical
columns, reagents, excipients and packaging components.

 

1.34.
“NDA” means a New Drug Application as defined in the Act.

 

1.35.
“Nonconforming Products” means any Products produced by Societal CDMO that: (a) do not conform to the Product Specifications
for such Product; or (b) exceed the quantity of Products ordered by Client pursuant to this Agreement or Statement of Work. Where the
context requires, Nonconforming Products are deemed to be Products for purposes of this Agreement.

 

1.36.
“Pass-Through Costs” means any fees, costs or expenses incurred by Societal CDMO from Third Parties in connection
with the acquisition of Materials and supplemental services necessary to perform the Services, in each case to the extent set forth in
the applicable Statement of Work or otherwise approved by Client in writing.

 

1.37.
“Person” means a corporation, association, joint venture, partnership, trust, business, individual, government or
political subdivision thereof, or any Governmental Authority.

 

1.38.
“Product” means the drug product(s) covered by this Agreement and produced as contemplated in and pursuant to the
Product Description.

 

1.39.
“Product Description” means those documents attached to a Statement of Work, which provide specific details about
each Product to be produced for Client by Societal CDMO under such Statement of Work.

 

1.40.
“Product Specifications” means the applicable quality control, quality assurance and other requirements, procedures,
guidelines and specifications for the manufacturing, packaging, labeling, testing, handling, dating and storage of a Product, each as
set forth in the applicable Registration for such Product or as may be required pursuant to any Regulatory Standards, and further including
the specifications attached to or referenced in the applicable Statement of Work, and as may be amended from time to time as required
by any Regulatory Standards or by the mutual written agreement of the parties

 

1.41.
“Product Warranty” shall have the meeting set forth in Section 9.5(a).

 

1.42.
“Quality Agreement” means the Quality Agreement for Contract Drug Manufacturing executed between Client and Societal
CDMO for any Product, which specifies the respective responsibilities for quality control and quality assurance activities consistent
with cGMPs with respect to the activities undertaken in accordance with of this Agreement.

 

    	-4-

     

    

 

1.43.
“Registrations” means all permits, licenses, approvals and authorizations granted by any Governmental Authority with
regard to any Product, including, without limitation, any NDAs for any Product.

 

1.44.
“Regulatory Standards” means (a) any and all permits, licenses, filings and certifications required by the FDA, including,
but not limited to cGMPs (b) any laws, rules, regulations and standards of any Governmental Authority, (including, without limitation,
the Environmental Protection Agency (“EPA”), the Occupational Safety and Health Administration (“OSHA”),
the Drug Enforcement Administration (“DEA”) and state and local authorities), that apply to the Manufacturing Facilities
or Societal CDMO’s processing, storage handling, or shipment of Materials or Products.

 

1.45.
“Release Date” means the date on which all Release Documents have been signed by Societal CDMO and approved by Client
in accordance with Section 2.10 for Finished Products that are finished (including, but not limited to, in final packaging) and ready
for delivery.

 

1.46.
“Release Documents” means, with respect to a Batch of Finished Product, the Certificate of Analysis or Conformance
and any other documents identified in the Quality Agreement or applicable Statement of Work as documents that will be provided to Client
by Societal CDMO upon Finished Product release.

 

1.47.
“Renewal Term” shall have the meaning set forth in Section 7.1.

 

1.48.
“Societal CDMO” shall have the meaning set forth in the preamble.

 

1.49.
“Societal CDMO Indemnitees” shall have the meaning set forth in Section 9.1.

 

1.50.
“Societal CDMO’s Property” shall have the meaning set forth in Section 5.4.

 

1.51.
“Societal CDMO’s Intellectual Property” means all Intellectual Property owned by or licensed to Societal CDMO,
including any of Societal CDMO’s Intellectual Property which is not developed in connection with this Agreement but which is used
in the design, production, and manufacturing of the Products (but, in each case, excluding any of Client’s Intellectual Property).

 

1.52.
“Services” shall have the meaning set forth in Section 2.1.

 

1.53.
“Statement of Work” shall refer to the document in a form approved by Societal CDMO and set forth on Exhibit A-1,
which details the particular Services to be performed for each project. Each Statement of Work shall be attached to this Agreement as
sequentially numbered exhibits (e.g., Exhibit A-2, Exhibit A-3, etc.).

 

1.54.
“Subcontractors” shall have the meaning set forth in Section 2.3.

 

1.55.
“Supplied Items” shall have the meaning set forth in Section 11.1.

 

1.56.
“Term” shall have the meaning set forth in Section 7.1.

 

1.57.
“Third Parties” means any Person except a Party or an Affiliate of a Party.

 

    	-5-

     

    

 

1.58.
“Trade Secret” means a formula, practice, process, design, instrument, pattern, commercial method, or compilation
of information not generally known or reasonably ascertainable by others by which Client can obtain an economic advantage over competitors
or customer.

 

1.59.
“Work-in-Process” means all Products that Societal CDMO has begun to Manufacture into Finished Products, but which
have not yet satisfied the requirements of Section 2.9 or Section 6.6.

 

2.
TERMS OF SERVICES

 

2.1.
Statement of Work. During the Term of this Agreement, Societal CDMO shall provide services as described in a Statement of Work
(the “Services”). Societal CDMO may conduct more than one project in connection with this Agreement, as mutually agreed
upon by the Parties and set forth in a written Statement of Work for each such project, which Statement of Work shall be signed by both
Parties prior to commencement of the Services. Each Statement of Work shall include the following information: (i) a description of the
project, (ii) the budget and payment schedule for the project, (iii) the timing or schedule for the project, and (iv) any other relevant
information. Each Statement of Work shall be incorporated by reference into this Agreement and shall be construed under the terms of
this Agreement and nothing contained in a Statement of Work shall be construed to amend or modify any provision of this Agreement. To
the extent the terms of any Statement of Work, or any other writing between the Parties (with the exception of a formal amendment to
this Agreement), conflicts with the terms of this Agreement, the terms of this Agreement shall control.

 

2.2.
Changes or Modifications. Any alteration, modification or other change to a Statement of Work will require execution by the Parties
of a Change Order. Each Change Order will set forth in sufficient detail the changes in Services and/or terms (e.g., term, timeline,
budget, payment schedule, deliverables, key personnel and/or overall level of responsibility), or other alteration to the Statement of
Work and each Change Order will be deemed attached to such Statement of Work and made a part thereof. Any Change Order will become effective
only upon the date of execution thereof by both Parties, unless the Change Order specifically sets forth a different effective date.
Both Parties agree to act in good faith to promptly identify, review and, if agreed by the Parties, execute Change Orders.

 

2.3.
Subcontractors; Use of Third-Party Vendors. Societal CDMO may employ or engage the service of such subcontractors as Societal
CDMO deems necessary to perform the Services required by this Agreement (the “Subcontractors”), subject to Client’s
prior, written approval in each case. Societal CDMO acknowledges and agrees that it shall be fully liable for all acts or omissions,
or other violations of this Agreement, relating to the use of such Subcontractors. Client further acknowledges and agrees that Societal
CDMO may acquire Materials or supplemental services through Third Parties in accordance with the terms of the applicable Statement of
Work, and that Client agrees to pay any Pass-Through Costs related to the use of such Third Parties. Notwithstanding the foregoing, Societal
CDMO will have no liability to the extent arising from the performance of the Services by Subcontractor: (i) that are chosen or requested
specifically by Client (except to the extent Societal CDMO is grossly negligent or in breach of this Agreement in its direction or oversight
of such Subcontractor); or (ii) if the Subcontractor is following the direct instructions of Client.

 

    	-6-

     

    

 

2.4.
Manufacturing Compliance Requirements. Societal CDMO shall Manufacture the Products in accordance with the applicable Product
Specifications, cGMPs, Regulatory Standards, and the terms and conditions of this Agreement, the Quality Agreement and the applicable
Statement of Work.

 

2.5.
Compliance with Laws. Societal CDMO represents, warrants and covenants that it: (i) has and shall maintain at all relevant times
the appropriate registrations, licenses and any other governmental authorizations required to enable it to lawfully and properly perform
the Services under this Agreement; (ii) shall perform all of its obligations under this Agreement in a professional and workmanlike manner
and in accordance with generally accepted standards of the pharmaceutical manufacturing industry, this Agreement, the Quality Agreement,
the applicable Statement of Work, and Societal CDMO’s SOPs to the extent not inconsistent with this Agreement, the Quality Agreement,
the applicable Statement of Work, cGMPs and other Regulatory Standards or the Product Specifications.

 

2.6.
Product Specifications. Each Statement of Work will include
or reference (a) the Product Specifications, (b) the API and specifications thereof; (c) the excipients and specifications thereof; (d)
any special requirements, including required sources, for the procurement of API and Materials; (e) the packaging and labeling specifications;
(f) any special equipment Societal CDMO is required to purchase to manufacture a Product; and any equipment and process parameters and
set points.

 

2.7.
Master Batch Record. Societal CDMO shall prepare and maintain
the Master Batch Record for the manufacture of each Product at its Manufacturing Facility. Any change to the Master Batch Record requires
the Client’s prior, written approval.

 

2.8.
Manufacturing Process. All API and other Materials will be
received and held in quarantine by Societal CDMO until testing has been reviewed and approved by Societal CDMO’s Quality Assurance
Department and all release documents have been produced with respect to such API and other Materials. On receipt of the signed Master
Batch Record from Client, Societal CDMO shall process the API and Materials at the Manufacturing Facility in accordance with the Master
Batch Record, any and all applicable Regulatory Standards, the Acceptance Criteria, cGMPs, the Product Specifications, the Quality Agreement,
Societal CDMO’s quality assurance and quality control practices and the other requirements of this Agreement and the applicable
Statement of Work.

 

2.9.
Product Release. Upon submission of agreed upon Product samples
for final testing, Societal CDMO shall prepare the Release Documents specific to each Batch of Finished Product and shall submit them,
at Societal CDMO’s cost, to Client no later than seven (7) Business Days following such final testing. Release Documents will not
be considered final unless and until Societal CDMO has performed a quality assurance review thereof. Client shall approve or reject the
Release Documents within five (5) Business Days from receipt of Release Documents. If Client approves Release Documents, Client shall
authorize Societal CDMO to release the Batch of Product and Societal CDMO shall issue the Certificate of Analysis with the Release Date.

 

    	-7-

     

    

 

2.10.
Packaging and Labeling. Societal CDMO shall properly pack,
label and ship Product as instructed by Client and otherwise in accordance with applicable Product Specifications, cGMPs, Regulatory
Standards, and the requirements of this Agreement, the Quality Agreement and the applicable Statement of Work. Label template will be
provided by the Client. Societal CDMO shall provide Client with shipment documentation showing Societal CDMO’s identification number
for the Product, the quantity of pieces in shipment, the number of cartons or containers in shipment, Societal CDMO’s name, the
bill of lading number, and the country of origin.

 

2.11.
Inspection. Products are subject to Client’s inspection
and approval or rejection notwithstanding Client’s prior receipt of or payment for the Product. Client shall have a reasonable
period of time, not to be less than ten (10) Business Days following receipt of the Product at Client’s final destination (“Inspection
Period”), to inspect all Product received under this Agreement and to inform Societal CDMO, in writing, of Client’s rejection
of any Nonconforming Product. Client may return to Societal CDMO any or all units of rejected Product that constitute Nonconforming Product
because they exceed the quantity stated in the Statement of Work by more than five percent (5%). If Client rejects any other Nonconforming
Product, Client may elect to require Societal CDMO, at Societal CDMO’s sole cost, subject to Section 9.4(b), to replace the rejected
Product at the location specified by Client (which may include Societal CDMO’s location, Client’s location or the location
of a third party) without limiting the exercise by Client of any other rights available to Client under this Agreement or pursuant to
applicable Law. All returns of Nonconforming Product to Societal CDMO are at Societal CDMO’s sole risk and expense. Product that
is not rejected within the Inspection Period will be deemed to have been accepted by Client; provided, however, that Client’s acceptance
of any Product will not be deemed to be a waiver or limitation of Societal CDMO’s obligations pursuant to this Agreement (or any
breach thereof), including those obligations with respect to Societal CDMO’s Product Warranty and Societal CDMO’s duty to
indemnify Client.

 

3.
CERTAIN OBLIGATIONS OF SOCIETAL CDMO

3.1.
Quality.

 

(a)
Societal CDMO shall at a minimum meet Client’s quality standards for the Products as agreed upon in the Quality Agreement. Societal
CDMO shall perform quality inspections and testing of Products before delivery and shall certify test results in the manner agreed upon
in the Quality Agreement.

 

(b)
If Societal CDMO fails to meet Client’s quality standards for the Products as agreed upon in the Quality Agreement, Societal CDMO
shall provide support as requested by Client to address and correct such quality concerns. In addition to its other rights and remedies,
Client may hold Societal CDMO responsible for documented costs associated with quality-issue investigation and containment to the extent
caused by Societal CDMO’s grossly negligent acts or omissions or material breach of this Agreement.

 

    	-8-

     

    

 

(c)
Societal CDMO shall provide Client, as part of release documentation, all Batch related documentation, including but not limited to executed
Batch Records, equipment data output, analytical and quality control test results and associated data

 

3.2.
Protection Against Supply Interruptions. In the
event that Societal CDMO identifies any foreseeable or anticipated event or circumstance that could interrupt or delay Societal CDMO’s
performance under this Agreement (“Delay Circumstance”), Societal CDMO shall promptly notify Client of any such Delay
Circumstance and use commercially reasonable efforts to minimize such Delay Circumstances.

 

3.3.
Duty to Advise. Societal CDMO shall promptly provide written
notice to Client of any of the following events or occurrences, or any facts or circumstances reasonably likely to give rise to any of
the following events or occurrences: (a) any failure for any reason by Societal CDMO to perform any of its obligations under this Agreement
or any Statement of Work; (b) any delay in delivery of Products; (c) any defects or quality problems relating to Products; (d) any deficiency
in the Materials; or (e) any failure by Societal CDMO, or its Subcontractors or common carriers, to comply with applicable Regulatory
Standards. In addition, Societal CDMO shall promptly notify Client in writing of any change in Societal CDMO’s professional certifications.

 

3.4.
Certain Changes.

 

(a)
Societal CDMO shall promptly make any changes Client directs in a Change Order, which may include changes in the Product Specifications,
inspection, testing, quality control, methods of packing and shipping or the date or place of delivery. Any changes pursuant to this
Section 3.4(a) will not affect the Price or time for delivery of Products unless (i) within a commercially reasonable timeframe after
Client’s notice to Societal CDMO of the change, Client receives from Societal CDMO written notice of a claim for adjustment with
all sufficient information and documentation regarding Societal CDMO’s costs and production timing resulting from such changes
to allow Client to perform an audit and verify such claim, and (ii) after auditing and verifying such claim, the results of such audit
indicate that, in order to implement such Client-requested changes, Societal CDMO’s actual out-of-pocket costs increased by a material
amount or that implementing such changes reasonably and appropriately caused a delay in the delivery date of any affected Products. Societal
CDMO may increase the prices hereunder in a per-unit amount solely to the extent necessary to compensate Societal CDMO for such commercially
reasonable cost increases (but not to allow for any additional margin). Nothing in this Section 3.4(a) including any disagreement with
Client as to any adjustment in price or time for performance, will excuse Societal CDMO from proceeding with this Agreement as changed.

 

    	-9-

     

    

 

(b)
Societal CDMO may not make any changes with respect to the Products or scope of this Agreement without Client’s advance written
approval, which may be given or withheld in Client’s in sole discretion.

 

4.
COMPENSATION AND PAYMENT

 

4.1.
Payments.

 

(a)
Generally. Except as otherwise provided in this Section 4.1 or any Statement of Work, as compensation for the Services performed
by Societal CDMO, Societal CDMO will invoice Client the fees set forth in the Statement of Work, in accordance with the invoicing schedule
set forth in the Statement of Work. Client shall pay Societal CDMO for all undisputed amounts within thirty (30) days after receipt of
an invoice.

 

(b)
Advance Payments. Client shall pay Societal CDMO an agreed upon percentage of the total fees set forth in the invoicing schedule
of each Statement of Work upon execution of such Statement of Work, if any (the “Advance Payment”). Societal CDMO
shall credit the Advance Payment against any subsequent invoices issued for the Services, until the amount of such credit is fully exhausted.
Societal CDMO may delay the commencement of the Services until the Advance Payment is paid by Client.

 

(c)
Milestone Payments. As set forth in the Statement of Work, Societal CDMO shall invoice Client the applicable fees set forth in
the Statement of Work upon completion of each milestone set out in the Statement of Work. For the avoidance of doubt, each activity that
is assigned a specific milestone price in the Statement of Work shall be treated as a separate milestone hereunder.

 

(d)
Budget Assumptions. Client agrees that the fees set out in each Statement of Work are based upon certain assumptions contained
therein and the fees may require adjustment if these assumptions are incorrect. Societal CDMO will notify Client upon any such adjustments.
The Parties shall in good faith discuss any corresponding fee adjustments and related amendments to be implemented through a Change Order.

 

(e)
Good Faith Dispute. In the event of any good faith dispute with regard to an invoice, Client shall notify Societal CDMO of such
dispute within fifteen (15) days of receipt of the invoice, and any undisputed portion of the invoice shall be paid as provided herein.
The Parties will work together in good faith to resolve any dispute with respect to an invoice. Any amounts owed to Societal CDMO shall
be paid within thirty (30) days of resolution of such dispute.

 

(f)
Late Fee. Client shall pay interest on undisputed past due accounts at a rate that is equal to the lesser of (i) 1.5% per month
or (ii) the maximum amount allowable by law.

 

(g)
Suspension of Services. Upon prior written notice to Client, Societal CDMO may suspend all Services under a Statement of Work
until all overdue undisputed outstanding invoices under such Statement of Work have been paid in full.

 

4.2.
Pass-Through Costs. Client shall reimburse Societal CDMO for all reasonable, approved Pass-Through Costs at Societal CDMO’s
cost plus an additional 10% as a handling fee. Societal CDMO shall invoice any such Pass-Through Costs on a monthly basis, which invoices
shall also include proper documentation of such expenses in order to receive reimbursement. Client shall pay Societal CDMO for all undisputed
amounts within thirty (30) days after receipt of such invoice. Upon prior written notice to Client, Societal CDMO may suspend all Services
under a Statement of Work until reimbursement for any undisputed Pass-Through Costs under such Statement of Work that are past due for
more than thirty (30) days have been paid in full.

 

    	-10-

     

    

 

4.3.
Taxes and Duties. Client shall be responsible for all taxes imposed on sales of products or Services by operation of law. The
consideration payable under any Statement of Work shall be net of any taxes imposed on the amounts payable to Societal CDMO hereunder.
Client will bear the cost of all duties, levies, tariffs, and similar charges (and any related interest and penalties) (together “Duties”),
however designated, arising from the performance of the Services by Societal CDMO, including without limitation those imposed as a result
of the shipping of materials (including API, materials, components, and final products) to, from or between different Societal CDMO site(s)
where required by Client. If such Duties are incurred by Societal CDMO, then Societal CDMO will be entitled to invoice Client for such
Duties at the time such Duties are incurred.

 

5.
PROPERTY

 

5.1.
Bailment.

 

(a)
All equipment and other tangible property of every description, including supplies, Materials, machinery, equipment, drawings, photographic
negatives and positives, artwork, copy layout, electronic data and other items, furnished by Client either directly or indirectly, to
Societal CDMO in connection with or related to this Agreement, or for which Societal CDMO has been at least partially reimbursed by Client,
but excluding any equipment or other tangible property approved by Client and any general-purpose raw materials, (collectively, “Bailed
Property”) is and will at all times remain the property of Client and be held by Societal CDMO on a bailment-at-will basis.

 

(b)
Only Client has any right, title or interest in and to Bailed Property, except for Societal CDMO’s limited right to use the Bailed
Property in the performance of Societal CDMO’s obligations under this Agreement. Societal CDMO shall not use the Bailed Property
for any other purpose. Societal CDMO shall maintain appropriate inventory and management control systems with respect to Bailed Property
and shall not move any Bailed Property from the Manufacturing Facility without the prior written approval by Client. Client may, at any
time, for any reason and without payment of any kind, retake possession of any Bailed Property without the necessity of payment or notice
to Societal CDMO, or a hearing or a court order, which rights, if any, are waived by Societal CDMO. Upon Client’s request, Bailed
Property will be released to Client or delivered to Client by Societal CDMO as soon as practicable. Societal CDMO’s continued holding
of Bailed Property after demand has been made by Client for delivery beyond what is practicable will substantially impair the value thereof,
and, accordingly, Client will be entitled to a court order of possession without any need or proving damages or a bond. To the fullest
extent permitted by law, Societal CDMO shall not allow any Encumbrance to be imposed on or attach to the Bailed Property through Societal
CDMO or as a result of Societal CDMO’s action or inaction, and Societal CDMO hereby waives any Encumbrance that it may have or
acquire in the Bailed Property.

 

    	-11-

     

    

 

(c)
Societal CDMO acknowledges and agrees that (i) Client is neither the manufacturer of the Bailed Property nor the manufacturer’s
agent and (ii) CLIENT HAS NOT MADE AND DOES NOT MAKE ANY REPRESENTATION OR WARRANTY WHATSOEVER, EITHER EXPRESS OR IMPLIED, AS TO THE
FITNESS, CONDITION, MERCHANTABILITY, DESIGN OR OPERATION OF THE BAILED PROPERTY OR ITS FITNESS FOR ANY PARTICULAR PURPOSE. Notwithstanding
the foregoing, if the bailment relationship described in this Section 5.1 is deemed to be a secured financing transaction, Societal CDMO
grants to Client a continuing security interest in any rights or interests Societal CDMO may have in the Bailed Property.

 

5.2.
Maintenance; Risk of Loss. Societal CDMO shall bear risk of
loss of and damage to Bailed Property. Societal CDMO shall, at its own expense, insure all Bailed Property with a special form property
policy, for its replacement value, in accordance with the terms of Section 13.7. As and when it is commercially reasonable to do so,
Client shall, at its sole cost and expense, maintain, repair, refurbish and replace Bailed Property. All replacement parts, additions,
improvements, and accessories that are paid for by the client will be noted as Client’s property upon their incorporation into
or attachment to the Bailed Property. All replacements of Bailed Property will also be Client’s property. Client shall replace
any missing components of or inserts to any Bailed Property.

 

5.3.
Inventory. Client shall provide a written inventory of all
Bailed Property that Client provides to Societal CDMO, and Societal CDMO shall set forth the location of all Bailed Property and otherwise
maintain such written inventory and provide a copy of this inventory to Client upon request. Societal CDMO shall mark all Bailed Property
permanently and conspicuously to identify it as the property of Client and indicate Client’s name and address. Societal CDMO shall
promptly sign any documents reasonably requested by Client to evidence all of Client’s rights to and interests in Bailed Property.
Societal CDMO grants to Client a limited and irrevocable power of attorney, coupled with an interest, to execute and record on Societal
CDMO’s behalf any documents with respect to Bailed Property that Client determines are reasonably necessary to reflect Client’s
interest in the Bailed Property.

 

5.4.
Societal CDMO’s Property. Unless otherwise agreed to
by Client in writing, Societal CDMO, at its sole expense, shall furnish, keep in good condition, and replace when necessary all equipment
and other items necessary or helpful for the production of the Products (excluding Bailed Property, “Societal CDMO’s Property”).

 

6.
SUPPLY OF API AND OTHER MATERIALS

 

6.1.
API Supply. Client shall prepay Societal CDMO in advance for all Pass-Through Costs for all API related to each Statement of Work
(in such quantities as are approved by Client in writing) in accordance with Section 4.2 of this Agreement. Societal CDMO shall purchase
all such API from a supplier mutually agreed to by the Parties.

 

    	-12-

     

    

 

6.2.
Material Supply.

 

(a)
Acquisition of Materials. Unless otherwise agreed to by the Parties, Societal CDMO shall purchase all Materials related to each
Statement of Work. Client shall reimburse Societal CDMO for all Pass-Through Costs related to such Materials (in such quantities as are
approved by Client in writing) in accordance with Section 4.2 of this Agreement.

 

(b)
Disposal of Materials. For any Materials purchased by Societal CDMO which have expired, or which no longer have any forecasted
requirements, Societal CDMO shall contact Client regarding instructions to either dispose of or ship such Materials to Client. If instructions
are not received from Client within thirty (30) days of such notice, Societal CDMO reserves the right, at Client’s cost, to dispose
of the Materials.

 

6.3.
Qualification of Materials and Vendors. Client is responsible for any vendor qualification of Client furnished materials and for
providing any required certificates of compliance for such Client furnished materials. If Client requests that Societal CDMO use a specific
vendor to purchase Materials and for all vendors selected by Societal CDMO to purchase Materials exclusively for Client, Societal CDMO
will be responsible to audit and secure approval of the vendor at Client’s expense.

 

6.4.
Testing. Within twenty (20) Business Days of receipt of each
shipment of Materials at the Manufacturing Facility, Societal CDMO shall commence: (a) release testing and such other activities as specified
in the appropriate quality document; and (b) inspecting each such shipment for obvious defects and for the shipment’s conformance
with any accompanying documentation. Societal CDMO shall promptly notify Client of any shipment of Materials which does not meet testing
specifications, fails to conform to its accompanying documentation, or otherwise carries obvious defects. Client shall pay the full price
and costs for any failed Services if a failure results because of defects or other non-conformities in the Materials, that (i) could
not have been discovered by Societal CDMO using the agreed testing methods and (ii) are not due to Societal CDMO’s gross negligence
in handling or storing such Materials.

 

6.5.
Storage of Materials. Societal CDMO shall label and store all Materials, Work-in-Process and Product in its possession from the
time of delivery of Materials to Societal CDMO at the Manufacturing Facility in accordance with all Regulatory Standards, and any agreed
storage instructions until delivery of the Finished Product(s) to Client. Societal CDMO shall maintain appropriate inventory and management
control systems to ensure that all Materials, Works-in-Process and Product are appropriately allocated.

 

6.6.
Capital Expenditures. Unless otherwise agreed in a separate agreement or set forth in a Statement of Work, if any capital equipment
expenditures are required to perform the Services (“Client Capital Requirements”), Societal CDMO will notify Client
of such Client Capital Requirements in writing before the Parties sign any Statement of Work for which such Client Capital Requirements
will be needed. Societal CDMO and Client will enter into a separate agreement or Statement of Work regarding the payment for and ownership
of the Client Capital Requirements.

 

    	-13-

     

    

 

6.7.
Acquisition of Approved Drugs. If Societal CDMO is required to buy any marketed drug product to complete the Services, Client
acknowledges that the purchases will be made by Societal CDMO on behalf of Client and that Societal CDMO will assume no responsibility
or liability whatsoever for the marketed drug product. All marketed drug product purchases will be prepaid by Client and, unless otherwise
agreed to between the Parties, Societal CDMO will only place an order for the marketed drug product once an agreed upon prepayment (in
the amount of the cost of such marketed drug) has been received.

 

6.8.
Import of API and Materials. If applicable, Societal CDMO and Client will reasonably cooperate to permit the import of Materials
into the United States. For import of API, Client or Client’s broker shall be designated as the “Importer of Record.”
Client’s obligation shall include obtaining the proper release of API from the local customs and health authorities in the country
of importation and obtaining the proper release of API from U.S. Customs and the FDA or the applicable Customs Agency and Regulatory
Authority.

 

6.9.
Client Assistance. Client shall provide Societal CDMO, in a timely fashion, with all relevant information as Societal CDMO may
reasonably request to perform the Services.

 

6.10.
Quota Restrictions. Notwithstanding anything to the contrary, the Parties acknowledge and agree that Societal CDMO’s obligation
to procure a given quantity of API, and Client’s obligations to purchase and take delivery of a given quantity of Finished Products,
in each case is subject to such Party having sufficient DEA quota (where applicable) to support such quantity of API or Finished Product,
as applicable (the “Quotas”). Societal CDMO will use commercially reasonable efforts to obtain sufficient Quotas based
on the then-current forecast provided by Client for the corresponding supply period.

 

7.
TERM AND TERMINATION

 

7.1.
Term. This Agreement shall commence as of the Effective Date and shall continue in full force and effect until (a) the fifth anniversary
of the Effective Date, or (b) such later date as may be required to complete a specific Statement of Work initiated hereunder (the “Initial
Term”). Except to the extent terminated sooner as provided in this Article 5, this Agreement shall automatically renew for
additional periods of twelve (12) months (a “Renewal Term”), and together with the Initial Term, the “Term”)
unless either Party notifies the other Party of its intention not to renew at least twelve (12) months (if prior to the successful completion
of process validation batches for the first Product) or twenty-four (24) months (after successful completion of process validation batches
for the first Product) prior to the expiration date of the Initial Term or any Renewal Term.

 

7.2.
Termination by Either Party. Without prejudicing any other rights or remedies available at law or in equity, either Party may
terminate this Agreement, and any Statement of Work upon the occurrence of any of the following events:

 

(a)
if the other Party is in material breach of any part of this Agreement that cannot be cured, or if the breach can be cured, such Party
fails to remedy the breach within (thirty) 30 days after receiving written notice of the breach from the other Party or if the non-breaching
Party; or

 

    	-14-

     

    

 

(b)
if the other Party (i) becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due, (ii) files or
has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily,
to any proceeding under any domestic or foreign bankruptcy or insolvency law, (iii) makes or seeks to make a general assignment for the
benefit of its creditors, or (iv) applies for or has appointed a receiver, trustee, custodian or similar agent appointed by order of
any court of competent jurisdiction to take charge of or sell any material portion of its property or business.

 

7.3.
Termination by Client. Client shall have the right to terminate this Agreement, or any Statement of Work, at any time with or
without cause upon ninety (90) days prior, written notice to Societal CDMO.

 

7.4.
Termination by Societal CDMO.

 

(a)
Societal CDMO shall have the right to terminate a Statement of Work:

 

(i)
If Client requires rescheduling any part of the Services covered by such Statement of Work for more than six (6) months; provided, however,
that Societal CDMO shall use commercially reasonably efforts to engage in meaningful discussions with Client in an effort to accommodate
any such requests prior to any termination under this subsection;

 

(ii)
if (A) the Services covered by such Statement of Work are not progressing according to the reasonable expectations of Client, and (B)
Societal CDMO and Client cannot agree on the appropriate scope changes or additional financial costs associated with such scope changes;
provided, that such lack of progress was due to reasons within Client’s reasonable control; provided, further, that Societal CDMO
shall use commercially reasonable efforts to work with Client for at least ninety (90) days to resolve such lack of progress prior to
any termination under this subsection;

 

(iii)
after six (6) months of inactivity on such Statement of Work; provided, that such inactivity was due to reasons within Client’s
reasonable control and not agreed to by Societal CDMO; provided, further, that Societal CDMO shall use commercially reasonable efforts
to engage in meaningful discussions with Client regarding such inactivity prior to any termination under this subsection; or

 

(iv)
if Societal CDMO reasonably determines that it is unable to perform the Services under such Statement of Work in accordance with applicable
regulatory requirements (including OSHA, DEA and FDA regulations) and applicable specifications; provided, however, that Societal CDMO
shall use commercially reasonable efforts to work with Client for at least ninety (90) days (after Societal CDMO provides Client with
notice of such determination) to make the necessary changes to the Services so that Societal CDMO can comply with applicable regulatory
requirements prior to any termination under this subsection.

 

    	-15-

     

    

 

(b)
Societal CDMO shall have the right to terminate this Agreement upon six (6) months prior, written notice to Client, if all Statements
of Work have been terminated pursuant to Section 7.4(a).

 

7.5.
Effects of Termination. Upon the effective date of any termination or expiration of this Agreement (or termination or expiration
of a Statement of Work without termination of the remainder of this Agreement, in which case, the following provisions shall only apply
with respect to such Statement of Work):

 

(a)
Societal CDMO shall:

 

(i)
credit any outstanding balances owed to Client including any un-applied Advance Payment against any outstanding invoices;

 

(ii)
promptly terminate all performance under this Agreement and under any outstanding Statement of Work;

 

(iii)
transfer title and deliver to Client all API, Material, work-in progress and Finished Product completed prior to the effectiveness of
the notice of termination; and

 

(iv)
return to Client all Bailed Property and any other property furnished by or belonging to Client, or dispose of such Bailed Property or
other property in accordance with Client’s instructions (provided that Client will reimburse Societal CDMO for the actual, reasonable
costs associated with such disposal).

 

(b)
Client shall pay:

 

(i)
any fees and expenses due to Societal CDMO for the Services rendered in accordance with this Agreement up to the date of completion,
expiration or termination including for reasonable wind-down activities associated with the Services;

 

(ii)
all actual costs incurred by Societal CDMO to complete activities associated with the completion, expiration or termination and close
of the Services rendered up to the date of completion, expiration or termination including, without limitation, disposal fees or delivery
fees that may be payable for any Materials owned by Client to be disposed of by Societal CDMO;

 

(iii)
any additional fees and costs incurred by Societal CDMO with Client’s prior, written approval relating to the Services that are
required to fulfill applicable regulatory and contractual requirements;

 

(iv)
except in the case of termination by Client pursuant to Section 7.2 or any non-renewal of this Agreement after the Initial Term, any
reasonable and actual documented expenses to restore the suite at the Manufacturing Facility that is dedicated to the manufacture of
Products to the condition of the suite prior to any build-out required pursuant to any Statement of Work; and

 

    	-16-

     

    

 

(v)
any reasonable out of pocket termination expenses resulting from the wind-down of Services from such early termination.

 

(c)
Client will arrange for the pickup from the Societal CDMO site of all Bailed Property (including, but not limited to, API and other Materials)
and other property owned by Client within ninety (90) days or as mutually agreed after the earlier of the completion, termination or
expiration of this Agreement or any applicable Statement of Work. Societal CDMO will charge Client a storage fee, as described in Section
11.3, for all Client property stored at the applicable Societal CDMO site after the ninetieth (90th) day following the completion,
termination or expiration of this Agreement or any applicable Statement of Work.

 

(d)
Each Party shall, except as required by any Governmental Authority:

 

(i)
return to the other Party or destroy all documents and tangible materials (and any copies) containing, reflecting, incorporating or based
on the other Party’s Confidential Information;

 

(ii)
permanently erase all of the other Party’s Confidential Information from its computer systems, except for copies that are maintained
as archive copies on its disaster recovery and/or information technology backup systems. Each Party shall destroy any such copies upon
the normal expiration of its backup files; and

 

(iii)
upon the other Party’s written request, certify in writing to such other Party that it has complied with the requirements of this
Section 7.4(d).

 

8.
INTELLECTUAL PROPERTY

 

8.1.
Client shall retain all rights, title and interests in and to Client’s Intellectual Property. Societal CDMO may only use Client’s
Intellectual Property as needed to perform Services under this Agreement.

 

8.2.
Societal CDMO is, and at all times remains, the sole and exclusive owner of Societal CDMO Intellectual Property. Except as otherwise
provided in this Section 8.2, no right, license or ownership interest under, in or to Societal CDMO Intellectual Property is granted
to Client. To the extent any Societal CDMO Intellectual Property is incorporated in any deliverable or other work product provided under
this Agreement, or is used in connection with the Manufacture of the Product, Societal CDMO hereby grants Client a non-exclusive, perpetual,
irrevocable, paid-up, royalty-free, transferable, sublicensable, worldwide license under such Societal CDMO Intellectual Property to
use, make, have made, sell, offer to sell, import and otherwise fully exploit any Product or any line extension thereof.

 

8.3.
All right, title and interest in and to any Inventions (including, but not limited to, any and all Intellectual Property rights and Trade
Secrets therein) conceived, generated, developed, derived, collected or reduced to practice by or on behalf of Societal CDMO, any of
its Subcontractors or Affiliates or any of its or their respective personnel in the course of performing services under this Agreement,
specifically related to the development, manufacture, testing, storage packaging, use and/or sale of any Product and/or which incorporates
or arises from any confidential information provided to Societal CDMO by or on behalf of Client (collectively, “Client Inventions”),
shall be the exclusive property of Client. Societal CDMO shall give Client written notice, as promptly as practicable, of all Client
Inventions.

 

    	-17-

     

    

 

8.4.
Societal CDMO hereby makes, and agrees to make (and to cause each of its Subcontractors and Affiliates and its and their respective personnel
to make), any and all assignments necessary to effect, exclusively and throughout the world, the ownership by Client of Client Inventions
under this Article 8.

 

8.5.
License to Client’s Intellectual Property. For the term of this Agreement, Client hereby grants to Societal CDMO, a non-exclusive,
paid-up, royalty-free, non-transferable license of Client’s Intellectual Property that are necessary or useful to perform the Services,
for use by Societal CDMO for the sole purpose of performing the Services for Client.

 

8.6.
Societal CDMO shall, and shall cause its Affiliates and Subcontractors and their respective personnel to, fully cooperate with, and sign
any documents reasonably requested by Client, to evidence, confirm, record and perfect such assignments and to obtain, maintain, enforce
and/or defend any rights assigned.

 

8.7.
No Conflict or Restrictions. Client acknowledges that, except as set forth in Section 2.6, nothing in this Agreement or any Statement
of Work will restrict Societal CDMO from using any Societal CDMO Intellectual Property, in the development and manufacture of products
for other Societal CDMO clients or for Societal CDMO’s own behalf.

 

9.
INDEMNIFICATION; LIMITATIONS OF LIABILITY

 

9.1.
Indemnification by Client. Client will defend and indemnify Societal CDMO, its Affiliates and their respective directors, officers,
employees and agents (collectively, the “Societal CDMO Indemnitees”) from all Losses relating to or arising from:
(i) the distribution of Client’s products or the use of Client’s products by patients either as part of or outside of the
scope of any clinical trials; (ii) any misrepresentation, negligence or willful misconduct by Client or any of its Affiliates and their
respective directors, officers, employees and agents (collectively, the “Client Indemnitees”); (iii) any breach by
Client of its obligations or warranties under this Agreement; or (iv) any claim of infringement of any Third Party’s intellectual
property rights in or by Client’s products or that is related to Societal CDMO’s use of Client’s Intellectual Property
to perform the Services. This indemnity will not apply to the extent that these Losses are those for which Societal CDMO is obligated
to indemnify the Client Indemnitees under Section 9.2.

 

9.2.
Indemnification by Societal CDMO. Societal CDMO will defend and indemnify the Client Indemnitees from all Losses relating to or
arising from: (i) any misrepresentation, negligence or willful misconduct by the Societal CDMO Indemnitees; (ii) any failure to Manufacture
Products in accordance with cGMP, where applicable; (iii) the breach by Societal CDMO of any of its obligations or warranties under this
Agreement; or (iv) any claim of infringement of any Third Party’s intellectual property rights in or by Societal CDMO’s Intellectual
Property that is used to perform the Services.

 

    	-18-

     

    

 

9.3.
Notice of Claims. If a claim occurs under Section 9.1 or 9.2, the indemnified Party will: (a) promptly notify the indemnifying
Party of the claim; (b) use commercially reasonable efforts to mitigate the effects of the claim; (c) reasonably cooperate with the indemnifying
Party in the defense of the claim; and (d) permit the indemnifying Party to control the defense and settlement of the claim, all at the
indemnifying Party’s cost and expense.

 

9.4.
Remedies; Limitation of Liability.

 

(a)
If Societal CDMO fails to perform any part of the Services in accordance with the terms of this Agreement or any applicable Statement
of Work, then without limiting any other remedies available to Client, Societal CDMO will, at Client’s option, either: (i) repeat
that part of the Services at Societal CDMO’s costs except that Client will supply the API (except as provided below); or (ii) reimburse
Client for the price for that part of the Services, excluding the cost of the API (except as provided below); provided, that Societal
CDMO shall supply the API pursuant to (i) and shall reimburse Client for the cost of API pursuant to (ii) if Societal CDMO’s failure
to perform Services is due to Societal CDMO’s gross negligence or willful misconduct.

 

(b)
Client shall retain title and risk of loss to any API; provided, that Societal CDMO shall reimburse Client for the loss of any API resulting
from Societal CDMO’s gross negligence or willful misconduct; provided that Societal CDMO’s obligation to reimburse Client
for the cost of such API shall not exceed the greater of (i) [***] percent ([***]%) of the work actually performed by Societal CDMO under
the applicable Statement of Work, and (ii) $[***].

 

(c)
EXCEPT FOR OBLIGATIONS TO MAKE PAYMENT OR WITH RESPECT TO LIABILITY FOR INDEMNIFICATION OR INFRINGEMENT OR MISAPPROPRIATION OF THE OTHER
PARTY’S INTELLECTUAL PROPERTY RIGHTS, UNDER NO CIRCUMSTANCES WHATSOEVER WILL EITHER PARTY BE LIABLE TO THE OTHER IN CONTRACT, TORT,
NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR (I) ANY (DIRECT OR INDIRECT) DELAY, PENALTY, LOSS OF PROFITS, LOSS OF PRODUCTION,
LOSS OF ANTICIPATED SAVINGS, LOSS OF BUSINESS, LOSS OF GOODWILL OR LOSS OF USE OF CLIENT’S PRODUCT, OR COSTS OF ANY SUBSTITUTE
SERVICE OR (II) ANY OTHER LIABILITY, DAMAGE, COST OR EXPENSE OF ANY KIND INCURRED BY THE OTHER PARTY OF AN INDIRECT OR CONSEQUENTIAL
NATURE, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF THESE DAMAGES.

 

9.5.
Product Warranty; No Debarment; Disclaimer.

 

(a)
The Parties recognize that certain Services, as identified in an applicable Statement of Work, are of a developmental or research nature
and the resultant products shall not be intended for commercial use. Client acknowledges and agrees that all timelines set for in such
Statements of Work are good-faith estimates. Societal CDMO hereby disclaims any warranties that the Services set forth in such Statements
of Work will be successfully completed, or successfully completed within the contemplated time period, despite Societal CDMO’s
commercially reasonable efforts to do so.

 

    	-19-

     

    

 

(b)
Societal CDMO represents, warrants, and covenants that the Finished Products, at the time of delivery to Client: (i) will have been Manufactured
in accordance with, and will fully comply with, the applicable Product Specifications, cGMPs, Regulatory Standards and the terms and
conditions of this Agreement, the Quality Agreement and the applicable Statement of Work, (ii) will not be adulterated or misbranded,
within the meaning of the Act, and (iii) will be free and clear from all Encumbrances.

 

(c)
Societal CDMO represents, warrants, and covenants that neither Societal CDMO nor any person employed or engaged by Societal CDMO in connection
with the Services has been debarred under section 306(a) or 306 (b) of the Act (or under any analogous law in any jurisdiction) and no
debarred person will in the future be employed or engaged by Societal CDMO in connection with any Services to be performed hereunder.

 

(d)
SOCIETAL CDMO HEREBY EXCLUDES ALL REPRESENTATIONS, WARRANTIES AND CONDITIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW,
OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, SOCIETAL CDMO MAKES NO EXPRESS
OR IMPLIED WARRANTY OR CONDITION: (I) FOR ANY PARTICULAR RESULTS FROM THE PERFORMANCE OF THE SERVICES OR WITH RESPECT TO ANY DATA OR
INFORMATION GENERATED THEREFROM, (II) OF FITNESS FOR A PARTICULAR PURPOSE, OR (III) OF MERCHANTABILITY FOR CLIENT’S PRODUCT, AND
THESE WARRANTIES AND CONDITIONS ARE EXPRESSLY EXCLUDED.

 

(e)
Client acknowledges that due to the uncertain and unpredictable nature of certain aspects of the Services, Societal CDMO may make commercially
reasonable recommendations before or after the start of the Services to ensure that the Product can be manufactured in a safe and effective
way in accordance with applicable regulatory requirements (including OSHA and FDA regulations, and the equivalent regulations in the
relevant territory) and applicable specifications. The Parties will discuss in good faith any changes or modifications to the Statement
of Work for such Services as required to implement such recommendations. If Client opts to proceed against Societal CDMO’s commercially
reasonable recommendations (including by failing to agree to a related change proposed by Societal CDMO), then Societal CDMO shall have
the right to terminate such Statement of Work pursuant to Section 7.4(a)(iv).

 

10.
DELIVERY AND SHIPPING

 

10.1.
Delivery. Shipments (if applicable) of Products and other deliverables will be made EXW (Incoterms 2020) Societal CDMO’s
Manufacturing Facility unless otherwise agreed. Risk of loss or damage to Products and deliverables will transfer to Client when Products
and other deliverables are loaded onto the carrier’s vehicle by Societal CDMO for shipment at the EXW point. Products and other
deliverables will be packaged for transport in accordance with Client’s instructions.

 

    	-20-

     

    

 

10.2.
Shipments. If Client requests Societal CDMO to coordinate collection of Products and other deliverables with shipper, Societal
CDMO shall proceed to do so as an agent of Client and at Client’s sole risk and expense on the basis that: (i) unless Client specifies
in writing a shipper that Societal CDMO is obliged to use, Client is deemed to have approved and accepted any shipper used by Societal
CDMO; (ii) any shipment charges will either be paid by Client direct to shipper or by Societal CDMO to shipper on Client’s behalf,
in which case Client shall reimburse Societal CDMO for the cost of shipment together with a handling fee of [***]%; (iii) Client shall
(x) obtain any applicable export license or other official authorization necessary to export Products and other deliverables, (y) be
responsible for complying with all applicable export laws and regulations and will pay any applicable export fees or taxes; and (z) be
responsible for maintaining adequate insurance (including transit insurance) for Products and deliverables at all times from delivery.

 

11.
STORAGE AFTER PRODUCT RELEASE OR PROJECT COMPLETION

 

11.1.
Storage of Supplied Items. Excluding retained samples or stability samples, and unless otherwise agreed between the Parties, Client
shall pay Societal CDMO a $[***] per month (or the equivalent in the relevant jurisdiction) per pallet, one pallet minimum, storage fee
if any commercial Batches of Finished Products (collectively, “Supplied Items”) are stored at Societal CDMO under
room temperature conditions for more than thirty (30) days after their release for shipment by Societal CDMO. This storage fee will increase
to $[***] per month (or the equivalent in the relevant jurisdiction) per pallet, one pallet minimum, for Supplied Items that are controlled
substances or for Supplied Items stored longer than ninety (90) days after their release for shipment by Societal CDMO. For Supplied
Items stored under other than room temperature conditions, the following storage fees will apply beginning thirty (30) days after the
Supplied Items have been released for shipment:

 

(a)
$[***] per cubic foot per month or $[***] per cubic foot per month after ninety (90) days (or the equivalent in the relevant jurisdiction)
for all Supplied Items stored at the Societal CDMO site under conditions of 2oC – 8oC;

 

(b)
$[***] per cubic foot per month or $[***] per cubic foot per month after ninety (90) days (or the equivalent in the relevant jurisdiction)
for all Supplied Items stored at the Societal CDMO site under frozen conditions; or

 

(c)
If Client requests storage at conditions different than those stated above, then this will be discussed and agreed between the Parties
on a separate basis.

 

11.2.
Right to Reject Storage. Societal CDMO reserves the right, upon written notice to Client, to refuse to store any Supplied Items,
at its sole discretion, for longer than ninety (90) days after release for shipment, and Client will assume all risk of loss or damage
to the Supplied Items stored for more than ninety (90) days after their release for shipment by Societal CDMO and it will be Client’s
responsibility to have appropriate insurance coverage in place for this risk. If Client asks Societal CDMO to destroy any Supplied Items,
Client shall be responsible for the cost of destruction.

 

11.3.
Stability Storage. Societal CDMO shall, at Client’s cost, destroy (or, if requested by Client, make available for pick up
by Client) all stability samples that remain in stability storage for more than thirty (30) days after the issuance of a report by Societal
CDMO for the final time point for that given storage condition (according to the agreed stability protocol), or after cancellation of
a given program. Client may request additional storage time for stability samples beyond thirty (30) days. If Societal CDMO agrees to
additional storage time, Client will be charged a storage fee of $[***] per liter per month. The cost of this storage will double after
ninety (90) days.

 

    	-21-

     

    

 

12.
REGULATORY FILINGS

 

12.1.
Prior to filing with any relevant regulatory authorities any clinical trial or new drug application that references Societal CDMO or
services Societal CDMO has performed, Client will give Societal CDMO a copy of the relevant chemical manufacturing and control (CMC)
sections of such application. This disclosure will permit Societal CDMO to verify that such application accurately describes the Services
that Societal CDMO has performed and the manufacturing and testing processes that Societal CDMO will perform under this Agreement. Societal
CDMO requires fourteen (14) days (for a new application) and ten (10) days (for revisions to an existing application) to perform this
review but the Parties may agree to a shorter time for the review as needed.

 

12.2.
If Client does not provide Societal CDMO with the documentation requested above within the time stipulated and if Societal CDMO reasonably
believes that Societal CDMO’s relationship with the regulatory authority may be jeopardized, Societal CDMO may, in its sole discretion,
delay or postpone the regulatory authority inspection which is or is equivalent to the FDA’s pre-approval inspection until Societal
CDMO has reviewed the requested documentation and is satisfied with its contents.

 

12.3.
If in Societal CDMO’s sole discretion, Societal CDMO determines that any of the information related to a regulatory filing provided
by Client is inaccurate or deficient in any manner whatsoever (the “Deficiencies”), Societal CDMO will notify Client
in writing of the Deficiencies. Until the Deficiencies have been resolved or agreement has been reached with Client for resolution, Societal
CDMO reserves the right not to participate in the regulatory authority inspection. If this occurs, Societal CDMO’s non-participation
in the inspection will not be construed as a breach of any of its obligations under this Agreement.

 

13.
MISCELLANEOUS

 

13.1.
Right to Visit, Audit and Inspect. Client, or representatives thereof (subject to such representatives entering into confidentiality
agreements reasonable acceptable to Societal CDMO), have the right to audit Societal CDMO’s facilities and systems and review documents
as they relate to the manufacture, packaging, testing, shipping and storage of Client’s products or deliverables at a time, date
and duration mutually agreed upon by the Parties. Societal CDMO will permit one standard cGMP compliance audit to be conducted annually
for at least two (2) business days with no more than two (2) people, but such period may be extended if reasonably agreed and warranted.
In addition, Client may conduct “for cause” audits if either Party received a warning letter or notice of other regulatory
actions from any Governmental Authority related to the products or deliverables subject to this Agreement. All visits, inspections and
audits shall be conducted in a manner that does not interrupt or impair in any significant manner the manufacturing operations of the
Manufacturing Facility. Client agrees to follow all internal Societal CDMO Standard Operating Procedures and safety policies when visiting
any Societal CDMO facility.

 

    	-22-

     

    

 

13.2.
Societal CDMO shall immediately notify Client if a Governmental Authority plans to conduct or conducts an inspection at its Manufacturing
Facilities that relates to Client’s Product. Societal CDMO’s obligations to Client with respect to any such inspection shall
be set forth in the Quality Agreement.

 

13.3.
Independent Contractor Status. The Parties are independent contractors under this Agreement, and nothing herein shall be construed
to create a partnership, joint venture or agency relationship between the Parties. Neither Party shall have the authority to enter into
agreements of any kind on behalf of the other Party and shall have no power or authority to bind or obligate the other Party in any manner
to any Third Party.

 

13.4.
Assignment. Neither Party may assign this Agreement and the rights and duties hereunder shall without the prior written consent
of the other Party (not to be unreasonably withheld); provided that each Party may assign this Agreement to an Affiliate or to a successor
to its business by virtue of merger, consolidation reorganization, stock sale or sale of all or substantially all of such Party’s
assets (or, in the case of Client, in connection with the sale of all or substantially all of its rights related to a Product, or the
licensing of rights with respect to a Product). This Agreement shall be binding upon and inure to the benefit of the Parties hereto,
their successors and permitted assigns, if any. This Agreement does not create any Third Party beneficiaries.

 

13.5.
Publicity. Neither Party nor any of its Affiliates or representatives shall (orally or in writing) publicly disclose, issue any
press release or make any other public statement, or otherwise communicate with the media, concerning the existence of this Agreement
or the subject matter hereof, without the prior written approval of the other Party (which shall not be unreasonably withheld, conditioned
or delayed), except if and to the extent that such Party is required to make any public disclosure or filing regarding the subject matter
of this Agreement: (a) by applicable law: (b) pursuant to any rules or regulations of any securities exchange of which the securities
of such Party or any of its Affiliates are listed or traded; or (c) in connection with enforcing its rights under this Agreement.

 

13.6.
Notice. Whenever a Party hereto is required to give any legal notice, demand or request with respect to this Agreement, such communication
shall be effective only if it is in writing and delivered by personal service, email transmission (with satisfactory evidence of receipt),
courier service (with satisfactory evidence of delivery) or mailed, certified mail, postage prepaid, addressed as follows:

 

If
to Client, to:

 

Cingulate
Therapeutics LLC

1901 W. 47th Place

Kansas City, KS 66205

Attn: General Counsel

Email: [***]

 

    	-23-

     

    

 

If
to Societal CDMO, to:

 

Societal
CDMO, Inc.

1300
Gould Dr.

Gainesville, GA 30504

Attn: Senior Vice President, Operations

Email:
[***]

 

Such
communications shall be effective when they are received by the addressee thereof, but if sent by certified mail in the manner set forth
above, they shall be effective two (2) business days after being deposited in the mail or if sent by courier or facsimile transmission
they shall be effective on the day after delivery. A Party may change its address for such communications by giving notice thereof to
the other Party in conformity with this Section 13.5.

 

13.7.
Confidentiality. The Confidentiality Agreement entered into between the Parties will apply to all confidential information about
the Parties and the Services to be conducted under this Agreement and any applicable Statement of Work and the Confidentiality Agreement
is incorporated herein by reference. If the Confidentiality Agreement expires or terminates before the expiration or termination of this
Agreement, then the terms of the Confidentiality Agreement will nonetheless continue to govern the Parties’ obligations of confidentiality
for the term of this Agreement and for five years thereafter. Notwithstanding anything to the contrary: (a) all of Client’s Intellectual
Property, as well as all Release Documents, Batch Records, Master Batch Records and all deliverables provided by Societal CDMO to Client
under this Agreement will be deemed to be Client’s confidential information (and not Societal CDMO’s confidential information)
for the purposes of such Confidentiality Agreement and (b) nothing in the Confidentiality Agreement will restrict Client from exercising
any of its rights under the license granted in Section 8.2.

 

13.8.
Insurance. Each Party will maintain at its sole cost and expense during the term of this Agreement and for three (3) years after
termination or expiration of this Agreement, (a) commercial general liability insurance (including product liability) with limits of
not less than $[***] million in the aggregate and (b) special form property policy covering Bailed Property for its replacement value.
Each Party shall also maintain such other policies of insurance of the types and amounts customarily carried by their respective businesses
which is sufficient to cover their respective liability under this Agreement. Each Party will provide evidence of this insurance upon
the request of the other Party and shall name the other Party as an additional insured with waiver of subrogation. The insurance certificate
shall provide for a minimum of thirty (30) days’ written notice to the insured of a cancellation of, or material change in, the
insurance. If a Party is unable to maintain the insurance policies required under this Agreement through no fault on the part of such
Party, then such Party shall promptly notify the other Party in writing and the Parties shall in good faith negotiate appropriate amendments
to the insurance provision of this Agreement in order to provide adequate assurances, provided that in no event shall such Party terminate
its insurance policies until such amendments to the insurance provision of this Agreement that are mutually agreed upon by the Parties
in writing are enacted.

 

    	-24-

     

    

 

13.9.
Force Majeure. Except for payment obligations, neither Party will be responsible for delay or failure in performance resulting
from acts beyond the reasonable control and without the fault or negligence of the Party, including, but not limited to, strikes or other
labor disturbances, lockouts, quarantines, communicable disease outbreaks, riots, wars, acts of terrorism, fires, floods, storms, interruption
of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components, or compliance with any
order or regulation of any government entity.

 

13.10.
Entire Agreement. This Agreement and all of its attachments, together with the Quality Agreement and any Statements of Work incorporated
herein, constitute the entire agreement between the Parties with respect to the Services. To the extent any of the provisions of this
Agreement conflict with the terms and conditions of the Quality Agreement, the Quality Agreement will control with respect to quality-related
matters, and this Agreement will control in all other respects.

 

13.11.
Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware,
without giving effect to the provisions thereof relating to conflicts of laws. The Parties hereby agree to submit to the jurisdiction
of the state or federal courts in the State of Delaware solely for purposes of any claim, action, suit or other proceeding enforcing,
interpreting or otherwise related to this Agreement.

 

13.12.
Non-Solicitation. During the term of this Agreement, and for one year after its termination, Client and its Affiliates will not,
directly or indirectly, solicit, induce, recruit, encourage or otherwise endeavor to cause or attempt to cause any officer, employee,
director or consultant of Societal CDMO or any of its Affiliates who became known to Client or its Affiliates in connection with the
Services, to terminate or discontinue their employment, contract or other relationship with Societal CDMO or any Societal CDMO Affiliate.
Notwithstanding any of the foregoing, the foregoing restrictions shall not restrict Client or any of its Affiliates from soliciting,
inducing, recruit, encouraging or otherwise endeavoring to cause or attempt to cause any person to terminate or discontinue their employment,
contract or other relationship with Societal CDMO or any Societal CDMO Affiliate, where such activities arise from (i) any advertisement
or announcement made at job fairs, in an online job posting or in other media not targeted to such person or (ii) a referral made to
Client or any of its Affiliates on the independent recommendation of a third party recruiter.

 

13.13.
Reservation of Rights. The right and remedies set forth in this Agreement are not exclusive but are in addition to any other remedies
the Parties may have at law or in equity. After the expiration or termination of this Agreement, the Parties shall retain all claims,
causes of action, defenses, and other rights that it may have at law or in equity.

 

13.14.
Headings. The headings of this Agreement are for purposes of reference only and shall not limit or otherwise affect the meaning
hereof.

 

    	-25-

     

    

 

13.15.
No Waiver; Modifications. No provision of this Agreement may be waived, amended or otherwise modified, except by a written agreement
signed by each Party hereto. The waiver by a Party of the breach of any provision hereof shall not be construed as a waiver of subsequent
breaches or as a continuing waiver of such breach.

 

13.16.
Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision
shall not affect the validity and enforceability of the other provisions hereof. If any provision of this Agreement, or the application
thereof to any person or entity or any circumstance, is invalid or unenforceable, (a) a suitable and equitable provision shall be substituted
therefore in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid and unenforceable provision
and (b) the remainder of this Agreement and the application of such provision to other persons, entities or circumstances shall not be
affected by such invalidity or enforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of
such provision, or the application thereof, in any other jurisdiction, unless invalidity of a certain provision affects the entire basis
of the bargain for a Party.

 

13.17.
Survival. The following provisions shall survive expiration or termination of this Agreement: Articles 5, 7, 8, 9, 11 and 13.

 

13.18.
Counterparts. This Agreement, the Quality Agreement and any Statement of Work may be executed simultaneously in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement will
become binding when any one or more counterparts hereof, individually or taken together, bear the signatures of both Parties. For the
purposes hereof, an electronic, .pdf or facsimile copy of this Agreement, the Quality Agreement or any Statement of Work, including signed
signature pages hereto, shall be deemed an original.

 

[Signature
page follows]

 

    	-26-

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the Effective Date by their duly authorized
representatives.

 

	Societal
                                            CDMO, Inc.

	 	Cingulate
                                            Therapeutics LLC

	 	 	 	 	 
	By	/s/
    Scott Rizzo	 	By	/s/
    Laurie A. Myers
	Name	Scott
    Rizzo	 	Name	Laurie
    A. Myers
	Title	Sr
    VP, Operations	 	Title	COO
	Date:	October
    24, 2022	 	Date:	October
    24, 2022

 

    	 

    	 

    

 

	Exhibit
A-1

 

form
of STATEMENT OF WORK

 

This
Statement of Work, dated as of ______________, 20__, is subject to that certain Master Services Agreement (the “Agreement”)
dated as of October 24, 2022, by and between Societal CDMO, Inc. & Affiliates (including IriSys, LLC and Recro Gainesville LLC) (“Societal
CDMO”) and Cingulate Therapeutics LLC (the “Client”). The terms and conditions of the Agreement are incorporated
by reference into this Statement of Work, and Client agrees to be bound by all of the terms and conditions of the Agreement applicable
hereto. Capitalized terms used in this Statement of Work and not defined herein shall have the meanings ascribed to such terms in the
Agreement.

 

Services
and scope of work to be performed, including required Materials (if any): [Scope of Work]

 

Payment
Terms:

 

For
the Services described in this Statement of Work, Client shall pay Societal CDMO [description
of payment terms] (U.S. Dollars).

 

	Term:	

 

Societal
CDMO’s Services shall commence on [Effective Date of the Statement of work] and
continue for a period of [INSERT TERM] months, to expire on [EXPIRATION DATE].

 

Other
Terms: [Other Terms]

 

	Societal
                                            CDMO, Inc.

	 	Cingulate
                                            Therapeutics LLC

	 	 	 	 	 
	By		 	By	
	Name		 	Name	
	Title		 	Title	
	Date:		 	Date:	          

 

    	1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]